Skip to Content



Leukemia Insights - Winter 2008

We believe that MDS will evolve as a major medical and societal problem as the US population ages and patients survive other malignancies. Thus the need for appropriate staging and risk stratification classifications and specific therapies for each subgroup of patients with MDS is clear. Ongoing research on the molecular basis of this disease will allow the development of new precise therapies for our patients. In our program we strive to complement our clinical experience with the latest concepts in the biology of this disease and believe in having therapeutic alternatives for all patients with MDS.

© 2015 The University of Texas MD Anderson Cancer Center